menu
    • menu
    [{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Biorasi"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase IV","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"11","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"Alfasigma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alfasigma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Alfasigma

    Menu

    Alfasigma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

                            Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Galapagos

                            Deal Size : $184.9 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Galapagos Completes Transaction to Transfer Jyseleca® Business to Alfasigma

                            Details : Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.

                            Product Name : Jyseleca

                            Product Type : Miscellaneous

                            Upfront Cash : $54.3 million

                            January 31, 2024

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Galapagos

                            Deal Size : $184.9 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

                            Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Juvenile.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2024

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Galapagos

                            Deal Size : $229.7 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Galapagos Signs Agreement to Transfer Jyseleca® Business to Alfasigma

                            Details : Galapagos transfers Jyseleca (filgotinib) to Alfasigma as part of its transformation into a biotech company focused on immunology and oncology, marking a significant milestone for the company.

                            Product Name : Jyseleca

                            Product Type : Miscellaneous

                            Upfront Cash : $54.7 million

                            January 02, 2024

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Galapagos

                            Deal Size : $229.7 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved FDF

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

                            Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

                            Product Name : Ocaliva

                            Product Type : Miscellaneous

                            Upfront Cash : $794.0 million

                            November 08, 2023

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved FDF

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved FDF

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of...

                            Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

                            Product Name : Ocaliva

                            Product Type : Miscellaneous

                            Upfront Cash : $794.0 million

                            September 26, 2023

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved FDF

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

                            Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Axial Spondyloarthritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

                            Details : Velusetrag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Pseudo-Obstruction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulodexide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Centro Medico del Noroeste

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Endothelial Protection in Post COVID-19 Patients With Sulodexide

                            Details : Sulodexide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : Sulodexide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Centro Medico del Noroeste

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifaximin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Biorasi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

                            Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 09, 2021

                            Lead Product(s) : Rifaximin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Biorasi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth